A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.137_2630
Abstract: (95% CI: 5.0 days-1.9 months; Fig. 1). At a median follow up of 4.15 years 6 patients treated at target dose were still alive and treatment-free, whereas the 13 patients treated at lower dose levels… read more here.
Keywords: novel multi; trial novel; action therapy; first human ... See more keywords